February 09, 2024
1 min watch
Save
VIDEO: Specialist calls approval of Vabysmo an important advance in treatment of RVO
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this expert perspective from Hawaiian Eye 2024, Roger A. Goldberg, MD, MBA, discusses the significance of the approval of Vabysmo from Genentech for the treatment of retinal vein occlusion.
Retinal vein occlusion (RVO) is often overlooked in the retinal space, Goldberg said.
“We think about AMD and DME first and then RVO third,” he said. “But I think the approval of Vabysmo is the most important advance in 2023 for the treatment of RVO.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Goldberg reports consulting for AbbVie, Annexon, Apellis, Biogen, Boehringer Ingelheim, EyePoint, Genentech, Outlook Therapeutics, Regeneron and Zeiss; speaking for Apellis, Biogen and Genentech; and serving as an independent research contractor for AffaMed, Alexion, Annexon, Apellis, Boehringer Ingelheim, Cognition, EyePoint, Genentech, Janssen, Neurotech, Novo Nordisk, OcuTerra and Unity Bio.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.